11th World Congress of Diabetes India is underway virtually this year

Health Care Comments Off

The 11th World Congress of Diabetes India started yesterday. Stalwarts of diabetes have joined hands with the International Associations and Bodies like ADA, EASD and International Hypoglycemia etc. on a virtual platform to discuss the latest happenings in diabetes across the globe.

Diabetes India was initiated by (Late) Dr Sadikot in 2002 with a group of Key opinion leaders and seniors with the sole purpose of carrying out National Level epidemiological research in the field of Diabetes. He was the Founder President of DiabetesIndia, who used to collaborate with International bodies and bring International faculty to India to exchange ideas.

Diabetes India with its Vision of “Accessible, Affordable & Accountable treatment for all people with Diabetes” worked as a common platform for various stakeholders to come together. Apart from regular CMEs at all levels, Zonal meetings were also regularly conducted across India.

The Prevalence of Diabetes in India study (PODIS) was a true effort of DiabetesIndia and Dr Sadikot led the team of researchers across India to come out with the first national level prevalence data on diabetes in India. The International Diabetes Federation (IDF) adopted the data to be incorporated into the IDF Atlas.

Diabetes India began holding its Annual meetings once in 2 years starting in the year 2002 and invited the best from across the world as faculty.  This was a clear changing phenomenon in India.  An International faculty of more than 25 has never been seen in the past. This trend continues even today and the 11th edition has over 60 foreign faculties.  DiabetesIndia also collaborated with many International groups like IDF, EASD, ISPAD, Atherosclerosis Society and many more.

DiabetesIndia believes in national level epidemiological studies that can change diabetes treatment across the country. The CINDI 2 study published in 2016 is an example. It plans to do many more studies in the years to come.

The meeting this year is unique in so many ways. The meeting has been arranged in a virtual platform due to the existing Covid situation. Highest number of international faculty that too in top positions are participating in this unique conference. The Dr Sadikot Oration and Dr Siddharth Shah Oration would be delivered by Top faculty from India. More than 4000 delegates across the Globe have been registered for this conference.

The official journal of Diabetes India “Diabetes and Metabolic Syndrome: Clinical Research and Reviews (Elsevier)” was started in 2004 and continues to have great readership. Dr Anoop Misra is the Editor-in-Chief of the journal.

We assure that all participants would enjoy this feast of knowledge exchange from national and international faculties.

We look forward to getting more people registered and be benefitted by this conference.

Dr SR Aravind, President, DiabetesIndia

Dr Banshi Saboo, Hon. Secretary, DiabetesIndia

HCFI Round Table Expert Zoom Meeting on “COVID 19 & Mucormycosis”

Health Care Comments Off

HCFI Dr KK Aggarwal Research Fund

15th and 22nd May, 2021, 11am-12pm

Key points from discussion

  • Many cases of mucormycosis are being reported during the second wave. Earlier there were sporadic cases. But then a spurt of cases was reported from Maharashtra, Gujarat and even Delhi. The speed at which it is spreading in the country is very alarming.
  • More than 1000 cases have been detected in a month and most of them are in medical colleges or big private hospitals.
  • It is not seen in other parts of the world. Risk factors are climate, genetic, large number of diabetic population, steroid overuse.
  • Mucormycosis is a fungal disease. Fungal spores are present in the environment – in the air and in the soil. Although rare, it is a serious disease. Hence, it is important to discuss its prevention and early detection.
  • Risk factors include poorly controlled diabetes, hematopoietic malignancy, prolonged neutropenia, solid or stem cell transplant. Use of unsterilized water in oxygen humidifier is another risk factor. Prediabetic persons may be at risk if they are prescribed steroids.
  • It presents as rhino-orbital-cerebral-mucormycosis, which involves the nose, paranasal sinuses, eyes and the brain. Pulmonary (most common); GI and cutaneous or disseminated mucormycosis are other forms of the disease. GI mucormycosis is common in children.
  • Initial symptoms include fever, perinasal and periorbital pain, congestion, nasal discharge. In advanced disease, nasal ulceration or necrotic lesion can occur.
  • Most patients present with unilateral sinusitis; in the later stage, the disease becomes bilateral. It can be diagnosed by color changes in the nasal mucosa, nasal endoscopy, be watchful in the third/fourth week after discharge, especially if the patient has diabetes. Sympathetic ophthalmitis is very rare.
  • Microscopy is the confirmatory diagnostic test. Crust or deep tissue material is required for diagnosis. In some hospitals in Maharashtra, KOH smears are done as a routine at discharge, for any patient who is hospitalized for more than 21 days.
  • First treatment option is intense medical treatment; surgery should be the last option.
  • Surgical removal of mucormycosis is a big challenge; surgery itself is associated with high morbidity, especially in the immunocompromised persons.
  • Prevention is the best treatment for this disease; proper oral and personal hygiene, wearing shoes, long trousers, full sleeve shirts and gloves when handling soil, good oral and nasal hygiene (povidone iodine), appropriate use of antibiotics and antifungals, tight glycemic control for first 3 months post Covid, optimised steroid use (use in right doses for the right time) and use of clean and sterile water in humidifier and oxygen therapy. Many ENT surgeons use amphotericin irrigation. Hydrogen peroxide irrigation can also be done; it is more economical.
  • There is no medical need for water in oxygen supplementation system; it only indicates continuous flow of oxygen. If sterile/distil water is not available, then at least boiled water should be used. The bottle should be cleaned every day.
  • Remove possible sources of fungus infection in hospitals such as oxygen humidifiers.
  • Don’t miss warning signs. Detect it early and start treatment at the earliest. Manifestations picked up in the nose are critical to saving the eyes. There is no role of prophylaxis.
  • Shortage of liposomal amphotericin is a challenge.  It is the drug of choice, but it is also a very nephrotoxic drug. Posaconazole, another drug can be used; it is supposed to be kidney safe. Avoid variconazole.
  • All case of blocked noses should not be considered as bacterial sinusitis. Be aggressive for microscopy, KOH and culture.
  • Good ENT examination at the time of discharge (nasal endoscopy) “with all safety measures”, probably when the patient is Covid-negative may be considered.
  • There should be robust data, which is regionally representative, on mucormycosis as it needs to be re-looked at, especially in Covid time, with regard to factors such as difference in clinical presentation etc.
  • There is a need to sensitise all healthcare workers on this issue.
  • There are now dedicated mucor wards in many tertiary care referral centers. Nursing care of high risk patients should be done very carefully.
  • Careful monitoring and management of diabetes should be given equal importance as Covid treatment in those Covid patients who have comorbid diabetes. This may be key to reducing the number of cases of mucormycosis.
  • There is a need to build up a referral mechanism and insist on good pharmacy and prescription practices.
  • Effective implementation of Drugs and Cosmetics Rules is required.
  • Strengthening of the primary healthcare is the need of the hour. Proper diagnostic facilities should be available in all PHCs and Health & Wellness Centers.
  • The cost of medicines is presently prohibitive.
  • There is an urgent need to follow preventive measures. Prevention of Covid-19 will automatically prevent mucormycosis.
  • A presentation on “Covid-19 associated Rhino-orbital-cerebral-mucormycosis (ROCM)” was given by Dr AK Grover, Chairman, Dept. of Ophthalmology, Sir Ganga Ram Hospital and Chairman, Vision Eye Centres, Siri Fort Road and West Patel Nagar, New Delhi
  • ROCM is a huge problem almost exclusive to India. In a review of published cases (up to May 13), out of total 101 cases, 82 were from India. 80% of patients had pre-existing diabetes and 76% patients had received steroids. Rhinological symptoms were the most common symptoms reported by almost 89% of patients.
  • Factors predisposing to RCOM include: diabetes/hyperglycemia, steroids, immunodeficiency, malignancy, stem cell transplantation and iron overload.
  • Lowering of innate immunity by Covid, lowered immunity due to use of steroids/tocilizumab, hyperglycemia aggravated by steroids, oxidative stress, high ferritin levels, zinc and use of antibiotics facilitating breakthrough infections may cause covid-associated ROCM. Not much is still known, except hyperglycemia is certainly an important contributory factor.
  • Diagnosis of ROCM has been divided into possible, probable and proven.
  • Possible ROCM: typical signs and symptoms in the clinical setting of recently (≤6 weeks) treated Covid-19, diabetes, immunosuppression, use of systemic steroids/tocilizumab, mechanical ventilation or oxygen supplementation
  • Probable ROCM: supportive evidence clinically and on diagnostic nasal endoscopy and/or contrast enhanced MRI/CT scan. No evidence on direct microscopy or culture or histopathology with special stains or molecular diagnostics
  • Proven ROCM: supportive evidence clinically and on diagnostic nasal endoscopy and/or contrast enhanced MRI/CT scan. Confirmation on direct microscopy or culture or histopathology with special stains or molecular diagnostics
  • Patient examination involves rhinological, ophthalmic and neurological examination in addition to systemic examination.
  • Ocular signs and symptoms of ROCM are periocular or facial edema, conjunctival congestion, sudden ptosis/double vision or motility restriction, proptosis and even sudden loss of vision.
  • Early presentation is lid edema and congestion; lid edema and motility restriction or ocular motility restriction and ptosis may also occur. In advanced stage, there is proptosis and formation of a large black eschar. The disease may become bilateral with necrosis. Cerebral involvement may occur in severe disease.
  • Along with medical therapy, sinus debridement surgery is done; sometimes exenteration requires to be done if there is more than two-quarter involvement of the orbit. This is a dilemma.
  • General signs and symptoms are regional/facial pain, fever, worsening headache, facial palsy, focal seizures.
  • Microscopic examination of tissue from nose (KOH) showing non septate hyphae, angioinvasion  is important for diagnosis. Direct microscopy has a sensitivity of 90%.
  • Contrast enhanced MRI is the imaging modality of choice.
  • There is tenting of the globe in the later stage. There may be bilateral optic nerve involvement.
  • Imaging is very important in assessment to find out the extent of involvement.
  • A multidisciplinary approach is critical for management.
  • Treatment is IV liposomal amphotericin, strict metabolic control and monitoring of renal function or IV posaconazole/isavuconazole. Aggressive debridement of PNS is required; turbinectomy/palatal wall/orbital wall resection may need to be done.
  • In the first wave, Sir Gangaram Hospital (SGRH) had 31 cases of mucormycosis; of these 29 had diabetes while in the second wave, there have been 89 cases (till 26th May); 72 had long-standing diabetes, while 17 had recently been diagnosed as having diabetes; 40 patients were hypertensive. Predominantly males were more affected than females. Most patients required oxygen supplementation.
  • A 6-weekly follow up is done for 3-6 months to assess regression or stabilization of disease, both clinically and via imaging.
  • Several reasons have been put forth for the epidemic of mucormycosis in India. To name a few: tropical climate, more dust/environment with spores, poor metabolic control and contamination of oxygen delivery.
  • Covid-associated ROCM can be prevented and can be treated adequately to prevent its devastating impact.
  • Recognise the red flags: purulent nasal discharge with or without epistaxis with sinusitis, decreased sensation inside the nose, nasal ulceration and necrosis, grey or reddish mucosa, black eschar in the nasal septum, palate, eyelid, face or orbital areas, facial pain on one side, swelling or numbness.
  • Prevention measures include education of the general public and medical community, strict glycemic control, rational use of steroids, use of distilled water in oxygen delivery systems, isotonic saline nasal spray at least twice daily.

Participants

Dr AK Agarwal

Dr Suneela Garg

Dr Ashok Grover

Dr Mahesh Verma

Dr Girdhar Gyani

Dr Anita Chakravarti

Dr Alex Thomas

Dr Ashok Gupta

Dr Sumit Mrig

Dr DR Rai

Dr Jayakrishnan Alapet

Mr Bejon Misra

Ms Balbir Verma

Mrs Upasana Arora

Dr Anuradha Sapra

Dr Reena Arora

Dr Promod Kumar

Dr Russell D’Souza, Australia

Dr KK Kalra

Dr Anil Kumar

Ms Ira Gupta

Dr S Sharma

Coronavirus Facts and Myth Buster

Health Care Comments Off

Dr KK Aggarwal Research Fund

With inputs from Dr Monica Vasudev

Small risk of bleeding and clotting disorders after AstraZeneca vaccine

There is a small increased risk of immune thrombocytopenic purpura (ITP) and other bleeding and vascular events associated with the Oxford/AstraZeneca vaccine, as per a nationwide analysis of over 2.5 million Scottish adults published in the journal Nature Medicine. These participants had received a first dose of the Oxford/AstraZeneca or Pfizer/BioNTech vaccine between December 2020 and April 2021.

  • Oxford/AstraZeneca was associated with a slightly increased risk of ITP up to 27 days after vaccination.
  • The estimated frequency was 1.13 cases per 100,000 first-dose vaccinations.
  • Those at greatest risk of ITP tended to be older (median age, ≥69 years old) and had at least one underlying chronic health problem, such as coronary heart disease, diabetes, or chronic kidney disease.
  • A very small increased risk of other arterial blood clot and bleeding events associated with Oxford/AstraZeneca up to 27 days after vaccination was also seen. However, there were insufficient data to conclude that there was an association between Oxford/AstraZeneca and cerebral venous sinus thrombosis.

However, the research suggests that the risks are comparable with those seen with other vaccines, including vaccines against hepatitis B, measles, mumps and rubella and influenza.

There was no evidence of an increased risk of the adverse events studied associated with the Pfizer/BioNTech vaccine.

(Source: Dawn OShea. Scottish study estimates risk of bleeding and clotting disorders after AstraZeneca vaccine - Medscape - Jun 09, 2021)

Patients with migraine have higher Covid incidence

A cross-sectional study from the United States has reported higher incidence of Covid-19 as well as heightened COVID symptoms in people who suffer migraines. The study was presented at the American Headache Society virtual meeting.

The study included 66,585 participants, aged 18 to 65 years, in the National Health and Wellness Survey (NHWS); 77% of the respondents were female. Of these, 7,759 people had a migraine diagnosis, while 58,827 did not have migraine. Overall, 3.82% of migraine patients self-reported having COVID-19 and 1.32% said they had tested positive for COVID. In contrast, 2.42% of the group without migraine self-reported having COVID and 0.82% of that group said they had tested positive (all P<0.001). Among those with Covid-19, those who had migraine reported more and higher percentages of COVID symptoms. They also were less likely to use healthcare resources if they tested positive for COVID.

Robert Shapiro, MD, PhD, of the University of Vermont in Burlington said, “Headache is a prevalent symptom of COVID-19, of long COVID, and of post-vaccination for COVID-19. Among COVID-19 inpatients, headache is associated with a positive prognosis. IL-6 levels are lower across the disease course. Headache is associated with 1 week shorter disease course overall. And if someone is admitted with COVID with a symptom of headache, it confers positive relative risk of survival of 2.2.”

(Source: Medpage Today, June 9, 2021)

CVST risk still higher with COVID-19 than with AZ/ J&J vaccination

Rates of cerebral venous sinus thrombosis (CVST) are much higher among patients with Covid-19 compared to persons who have been vaccinated with either the AstraZeneca or the Johnson & Johnson (J&J) vaccine, suggests a study published in the Journal of the American College of Cardiology on June 8.

The rate of CVST associated with the two vaccines was estimated based on the publicly reported data, which was compared to the rate observed among patients hospitalized with Covid-19 and in comparison with the estimated incidence rates among the US population before the pandemic. Data from the United Kingdom Medicines and Healthcare products regulatory agency and the US Centers CDC was used to report the number of events per vaccinated people with the AstraZeneca and Johnson & Johnson vaccines, respectively.

The SVIN COVID-19 multinational study of cerebrovascular events was used to find CVST rates among patients hospitalized with COVID-19. Latest available data from the Nationwide Inpatient Sample database from March and April 2018 were used to report the weighted monthly incidence of CVST before the pandemic.

  • Results showed that as of April 14, 2021, there were 77 CVST cases among 21,200,000 AstraZeneca vaccine recipients reported by the UK Medicines and Healthcare Products Regulatory Agency (3.6 per million; 99% CI, 2.7 – 4.8 per million).
  • As of April 13, 2021, the Centers for Disease Control and Prevention reported six cases of CVST among 6.85 million vaccinated people (0.9 per million; 99% CI, 0.2 – 2.3 per million).
  • In the SVIN COVID-19 registry, 3 of 14,483 patients hospitalized with COVID-19 had CVST (207.1 per million; 99% CI, 23.3 – 757.7 per million).
  • In the Nationwide Inpatient Sample, the weighted average rate of CVST in the US population for March and April 2018 was 2.4 per million (99% CI, 2.1 – 2.6 per million).

The authors conclude: “CVST is rare in the general population and after adenovirus-based SARS-CoV-2 vaccination, but appears to be several-fold more common in hospitalized patients with COVID-19.

Additional research is required to fully elucidate the event rates, to understand the risk factors for vaccine-associated CVST and to identify strategies to prevent it. In the meantime, transparent realistic communication of the risk estimates will be helpful for shared decision making between patients and clinicians.”

(Source: CVST risk still higher with COVID-19 than with AZ, J&J vaccination - Medscape - Jun 10, 2021)

« Previous Entries Next Entries »